Narrative review / 2016
Analysis of orlistat trials found that published papers reported only 3% to 33% of investigator-reported adverse events due to post hoc filters.
Researchers analyzed 8,716 pages of clinical study reports (CSRs) and protocols from seven randomized placebo-controlled trials of orlistat (4,225 participants) and compared them with published papers. Only 3% to 33% of investigator-reported adverse events appeared in publications due to post hoc filters, despite six of seven papers claiming all adverse events were recorded. In one trial, orlistat-treated participants experienced significantly more days with adverse events than placebo (22.7 d vs. 14.9 d, p < 0.0001) and more severe events, details omitted from CSRs and publications. A key limitation is that the analysis was restricted to one drug tested in the mid-1990s, which may not apply to newer drugs.
- Study type
- Document analysis of clinical study reports, protocols, and publications
- Who was studied
- 4,225 participants across 7 randomized placebo-controlled trials of orlistat
- What was measured
- Reporting and summarization of adverse events across protocols, CSRs, and papers
THE PAPER
Assessment of Adverse Events in Protocols, Clinical Study Reports, and Published Papers of Trials of Orlistat: A Document Analysis.
Schroll JB, Penninga EI, Gøtzsche PC. PLoS Med, 2016.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.